Human insulin Market - Global Industry Analysis

Market Overview     

The global Human insulin market accounted for USD 33.7 Billion in 2020 and is expected to reach USD 68 Billion by 2028, growing at a CAGR of around 8.9% between 2021 and 2028.      

Human insulin is the term that describes synthetic insulin which is grown in a laboratory to mimic the insulin in humans. In a laboratory, it is created by growing insulin proteins within E-coli bacteria (Escherichia coli). It is mainly available in two forms, a short acting (regular) form and an intermediate acting (NPH) form. Human insulin was developed as an insulin that could be created in large amounts at a relatively low cost. It can be administered orally or through insulin infusion devices. Some conventional insulin infusion devices are syringes, insulin pumps, and injection pens. These devices are used to deliver insulin on time and regularly.

COVID-19 Impact Analysis  

The global human insulin market has witnessed a slight decline in the sales for short term to the lockdown enforcement placed by governments in order to contain COVID spreading. The restrictions imposed by various nations to contain COVID had stopped the production resulting in a disruption across the whole supply chain. However, the global markets are slowly opening to their full potential and theirs a surge in demand. The market would remain bullish in upcoming year.  Rising support from governments and several companies can help in the fight against this disease. Overall, almost every sector is anticipated to be impacted by the pandemic.

The significant decrease in the global Human insulin market size in 2020 is estimated on the basis of the COVID-19 outbreak and its negative impact on the economies and industries across the globe. Various scenarios have been analyzed on the basis of inputs from various secondary sources and the current data available about the situation.

Growth Factors

The global human insulin market is likely to see noteworthy development in the years to come. This development in global human insulin market is attributed owing to the rising market demand for human insulin analogs, increasing risk of diabetes, favorable medical reimbursements, and technological enactments in the field of human insulin delivery devices. An insulin routine is often needed in the treatment of gestational diabetes and diabetes related with specific syndromes or conditions (such as chemical or drug-induced diabetes, pancreatic diseases, insulin-receptor disorders, endocrinopathies, and specific genetic syndromes). In all cases of insulin employment, the dosage of insulin must be balanced and individualized with exercise and medical nutrition therapy, thereby boosting the global human insulin market.

Increasing technical advancements is also one of the reasons for the growth of the global human insulin market. For instance, in June 2018, Eli Lilly and Company’s Humulin R U-500 (that was used in insulin pumps) displayed greater A1C lowering in adults suffering from type 2 diabetes. This was compared extraordinary in comparison to MDI (multiple daily injections), thereby driving the growth of global human insulin market.

Report Scope:  

Segment Analysis Preview  

Based on product, drugs were likely to add up for the biggest market share of the global human insulin market and are expected to stay the same in the near future. Requirement for biosimilar drugs is sturdy in both developing and developed nations owing to its low-cost therapy. This is boosted by the requirement for the best valuable therapy, which can frequently be expensive. Biosimilar insulin drug might provide a less-pricy option to current human insulin biologics, thus boosting the global human insulin market.

Regional Analysis Preview  

North America has been leading the worldwide human insulin market and is anticipated to continue on the dominant position in the years to come. The factors such as growing old age population, rising prevalence of diabetes, increasing healthcare awareness, improvement in reimbursement policies, and surge in clinical trials driving the growth of human insulin in North America.

Key Market Players & Competitive Landscape

Some of the major players of the global human insulin market include Eli Lilly, GlaxoSmithCline, Biocon, Sanofi Aventis, Julphar, Novo Nordisk, SemBioSys, and Wockhardt among others.

The global Human insulin Market is segmented as follows:

By Products

• Drugs
  • Insulin Analogs and Biosimilars
  • Human Insulin Biologics
• Drug Delivery Devices
  • Pens
  • Pen Needles
  • Syringes

By Applications

• Insulin dependent diabetes mellitus (Type 1)
• Non-Insulin dependent diabetes mellitus (Type 2)

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

• Chapter No. 1 Introduction
  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. USP & Key Offerings
  • 1.2. Key Benefits for Stakehulders
  • 1.3. Target Audience
  • 1.4. Report Scope
• Chapter No. 2 Executive Summary
  • 2.1. Key Findings
    • 2.1.1. Top Investment Pockets
      • 2.1.1.1. Market Attractiveness Analysis, By Product
      • 2.1.1.2. Market Attractiveness Analysis, By Application
      • 2.1.1.3. Market Attractiveness Analysis, By Region
  • 2.2. Market Snapshot
  • 2.3. Global Human insulin Market, 2016 – 2028 (USD Billion)
  • 2.4. Insights from Primary Respondents
• Chapter No. 3 COVID 19 Impact Analysis
  • 3.1. Impact Assessment of COVID-19 Pandemic, By Region
    • 3.1.1. North America
    • 3.1.2. Europe
    • 3.1.3. Asia Pacific
    • 3.1.4. Latin America
    • 3.1.5. The Middle-East and Africa
  • 3.2. Quarterly Market Revenue and Forecast by Region 2020 & 2021
  • 3.3. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Billion)
  • 3.4. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Billion)
  • 3.5. Key Strategies Undertaken by Companies to Tackle COVID-19
    • 3.5.1. Company Quarterly Revenue Analysis, 2019 & 2020
  • 3.6. Short Term Dynamics
  • 3.7. Long Term Dynamics
• Chapter No. 4 Human insulin Market – Product Segment Analysis
  • 4.1. Overview
    • 4.1.1. Market Revenue Share, By Product, 2020 & 2028
  • 4.2. Drugs
    • 4.2.1. Market Size and Forecast, By Region (USD Billion)
    • 4.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 4.2.3. Key Market Trends, Growth Factors, & Opportunities
  • 4.3. Drug Delivery Devices
    • 4.3.1. Market Size and Forecast, By Region (USD Billion)
    • 4.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 4.3.3. Key Market Trends, Growth Factors, & Opportunities
• Chapter No. 5 Human insulin Market – Application Segment Analysis
  • 5.1. Overview
    • 5.1.1. Market Revenue Share, By Application, 2020 & 2028
  • 5.2. Insulin dependent diabetes mellitus (Type 1)
    • 5.2.1. Market Size and Forecast, By Region (USD Billion)
    • 5.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 5.2.3. Key Market Trends, Growth Factors, & Opportunities
  • 5.3. Non-Insulin dependent diabetes mellitus (Type 2)
    • 5.3.1. Market Size and Forecast, By Region (USD Billion)
    • 5.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 5.3.3. Key Market Trends, Growth Factors, & Opportunities
  • 6.1. Overview
    • 6.1.1. Global Market Revenue Share, By Region, 2020 & 2028
    • 6.1.2. Global Market Revenue, By Region, 2016 – 2028 (USD Billion)
  • 6.2. North America
    • 6.2.1. North America Market Revenue, By Country, 2016 – 2028 (USD Billion)
    • 6.2.2. North America Market Revenue, By Product, 2016 – 2028
    • 6.2.3. North America Market Revenue, By Application, 2016 – 2028
    • 6.2.5. U.S.
      • 6.2.5.1. U.S. Market Revenue, By Product, 2016 – 2028
      • 6.2.5.2. U.S. Market Revenue, By Application, 2016 – 2028
    • 6.2.6. Canada
      • 6.2.6.1. Canada Market Revenue, By Product, 2016 – 2028
      • 6.2.6.2. Canada Market Revenue, By Application, 2016 – 2028
    • 6.2.7. Mexico
      • 6.2.7.1. Mexico Market Revenue, By Product, 2016 – 2028
      • 6.2.7.2. Mexico Market Revenue, By Application, 2016 – 2028
  • 6.3. Europe
    • 6.3.1. Europe Market Revenue, By Country, 2016 – 2028 (USD Billion)
    • 6.3.2. Europe Market Revenue, By Product, 2016 – 2028
    • 6.3.3. Europe Market Revenue, By Application, 2016 – 2028
    • 6.3.5. Germany
      • 6.3.5.1. Germany Market Revenue, By Product, 2016 – 2028
      • 6.3.5.2. Germany Market Revenue, By Application, 2016 – 2028
    • 6.3.6. France
      • 6.3.6.1. France Market Revenue, By Product, 2016 – 2028
      • 6.3.6.2. France Market Revenue, By Application, 2016 – 2028
    • 6.3.7. U.K.
      • 6.3.7.1. U.K. Market Revenue, By Product, 2016 – 2028
      • 6.3.7.2. U.K. Market Revenue, By Application, 2016 – 2028
    • 6.3.8. Italy
      • 6.3.8.1. Italy Market Revenue, By Product, 2016 – 2028
      • 6.3.8.2. Italy Market Revenue, By Application, 2016 – 2028
    • 6.3.9. Spain
      • 6.3.9.1. Spain Market Revenue, By Product, 2016 – 2028
      • 6.3.9.2. Spain Market Revenue, By Application, 2016 – 2028
    • 6.3.10. Rest of Europe
      • 6.3.10.1. Rest of Europe Market Revenue, By Product, 2016 – 2028
      • 6.3.10.2. Rest of Europe Market Revenue, By Application, 2016 – 2028
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Market Revenue, By Country, 2016 – 2028 (USD Billion)
    • 6.4.2. Asia Pacific Market Revenue, By Product, 2016 – 2028
    • 6.4.3. Asia Pacific Market Revenue, By Application, 2016 – 2028
    • 6.4.5. China
      • 6.4.5.1. China Market Revenue, By Product, 2016 – 2028
      • 6.4.5.2. China Market Revenue, By Application, 2016 – 2028
    • 6.4.6. Japan
      • 6.4.6.1. Japan Market Revenue, By Product, 2016 – 2028
      • 6.4.6.2. Japan Market Revenue, By Application, 2016 – 2028
    • 6.4.7. India
      • 6.4.7.1. India Market Revenue, By Product, 2016 – 2028
      • 6.4.7.2. India Market Revenue, By Application, 2016 – 2028
    • 6.4.8. South Korea
      • 6.4.8.1. South Korea Market Revenue, By Product, 2016 – 2028
      • 6.4.8.2. South Korea Market Revenue, By Application, 2016 – 2028
    • 6.4.9. South-East Asia
      • 6.4.9.1. South-East Asia Market Revenue, By Product, 2016 – 2028
      • 6.4.9.2. South-East Asia Market Revenue, By Application, 2016 – 2028
    • 6.4.10. Rest of Asia Pacific
      • 6.4.10.1. Rest of Asia Pacific Market Revenue, By Product, 2016 – 2028
      • 6.4.10.2. Rest of Asia Pacific Market Revenue, By Application, 2016 – 2028
  • 6.5. Latin America
    • 6.5.1. Latin America Market Revenue, By Country, 2016 – 2028 (USD Billion)
    • 6.5.2. Latin America Market Revenue, By Product, 2016 – 2028
    • 6.5.3. Latin America Market Revenue, By Application, 2016 – 2028
    • 6.5.5. Brazil
      • 6.5.5.1. Brazil Market Revenue, By Product, 2016 – 2028
      • 6.5.5.2. Brazil Market Revenue, By Application, 2016 – 2028
    • 6.5.6. Argentina
      • 6.5.6.1. Argentina Market Revenue, By Product, 2016 – 2028
      • 6.5.6.2. Argentina Market Revenue, By Application, 2016 – 2028
    • 6.5.7. Rest of Latin America
      • 6.5.7.1. Rest of Latin America Market Revenue, By Product, 2016 – 2028
      • 6.5.7.2. Rest of Latin America Market Revenue, By Application, 2016 – 2028
  • 6.6. The Middle-East and Africa
    • 6.6.1. The Middle-East and Africa Market Revenue, By Country, 2016 – 2028 (USD Billion)
    • 6.6.2. The Middle-East and Africa Market Revenue, By Product, 2016 – 2028
    • 6.6.3. The Middle-East and Africa Market Revenue, By Application, 2016 – 2028
    • 6.6.5. GCC Countries
      • 6.6.5.1. GCC Countries Market Revenue, By Product, 2016 – 2028
      • 6.6.5.2. GCC Countries Market Revenue, By Application, 2016 – 2028
    • 6.6.6. South Africa
      • 6.6.6.1. South Africa Market Revenue, By Product, 2016 – 2028
      • 6.6.6.2. South Africa Market Revenue, By Application, 2016 – 2028
    • 6.6.7. Rest of Middle-East Africa
      • 6.6.7.1. Rest of Middle-East Africa Market Revenue, By Product, 2016 – 2028
      • 6.6.7.2. Rest of Middle-East Africa Market Revenue, By Application, 2016 – 2028
• Chapter No. 7: Human insulin Market – Industry Analysis
  • 7.1. Introduction
  • 7.2. Market Drivers
    • 7.2.1. Driving Factor 1 Analysis
    • 7.2.2. Driving Factor 2 Analysis
  • 7.3. Market Restraints
    • 7.3.1. Restraining Factor Analysis
  • 7.4. Market Opportunities
    • 7.4.1. Market Opportunity Analysis
  • 7.5. Porter’s Five Forces Analysis
  • 7.6. PEST Analysis
  • 7.7. Regulatory Landscape
  • 7.8. Technology Landscape
  • 7.9. Regional Market Trends
    • 7.9.1. North America
    • 7.9.2. Europe
    • 7.9.3. Asia Pacific
    • 7.9.4. Latin America
    • 7.9.5. The Middle-East and Africa
  • 7.10. Pricing Analysis
  • 7.11. Value Chain Analysis
  • 7.12. Downstream Buyers
  • 7.13. Distributors/Traders List
• Chapter No. 8: Competitive Landscape
  • 8.1. Company Market Share Analysis – 2019
    • 8.1.1. Global Human insulin Market: Company Market Share, 2019
    • 8.1.2. Global Human insulin Market, Company Market Revenue, 2016 – 2019 (USD Billion)
    • 8.1.3. Global Human insulin Market, Company Y-o-Y Growth, 2017 – 2019 (%)
    • 8.1.4. Global Human insulin Market: Radar Determinant Chart, 2019
  • 8.2. Strategic Developments
    • 8.2.1. Acquisitions & Mergers
    • 8.2.2. New Product Launch
    • 8.2.3. Regional Expansion
  • 8.3. Company Strategic Developments – Heat Map Analysis
• Chapter No. 9: Company Profiles
  • 9.1. GlaxoSmithCline
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Product Portfolio
    • 9.1.4. Financial Overview
    • 9.1.5. Operating Business Segments
    • 9.1.6. Business Performance
    • 9.1.7. Recent Developments
  • 9.2. Eli Lilly
  • 9.3. Sanofi-Aventis
  • 9.4. Biocon
  • 9.5. Novo Nordisk
  • 9.6. Julphar
  • 9.7. Ypsomed AG
  • 9.8. SemBioSys
  • 9.9. Wockhardt
• Chapter No. 10: Marketing Strategy Analysis
  • 10.1. Marketing Channel
  • 10.2. Direct Marketing
  • 10.3. Indirect Marketing
  • 10.4. Marketing Channel Development Trends
  • 10.5. Economic/Pulitical Environmental Change
• Chapter No. 11: Research Methodology
  • 11.1. Research Methodology
  • 11.2. Phase I - Secondary Research
  • 11.3. Phase II - Data Modeling
    • 11.3.1. Company Share Analysis Model
    • 11.3.2. Revenue Based Modeling
  • 11.4. Phase III - Primary Research
  • 11.5. Research Limitations
    • 11.5.1. Assumptions

Table Of Figures

List of Figures 

FIG NO. 1. Market Attractiveness Analysis, By Product
FIG NO. 2. Market Attractiveness Analysis, By Application
FIG NO. 3. Market Attractiveness Analysis, By Region
FIG NO. 4. Global Human insulin Market Revenue, 2016 – 2028 (USD Billion)
FIG NO. 5. Impact of COVID-19 Pandemic in North America Countries
FIG NO. 6. Market Revenue Share, By Product, 2020 & 2028 
FIG NO. 7. Global Human insulin Market for Drugs, Revenue (USD Billion) 2016 – 2028
FIG NO. 8. Comparative Revenue Analysis of Human insulin Market for Drugs, By Country, 2020 & 2028
FIG NO. 9. Global Human insulin Market for Drug Delivery Devices, Revenue (USD Billion) 2016 – 2028
FIG NO. 10. Comparative Revenue Analysis of Human insulin Market for Drug Delivery Devices, By Country, 2020 & 2028
FIG NO. 15. Market Revenue Share, By Application, 2020 & 2028
FIG NO. 16. Global Human insulin Market for Insulin dependent diabetes mellitus (Type 1), Revenue (USD Billion) 2016 – 2028
FIG NO. 17. Comparative Revenue Analysis of Human insulin Market for Insulin dependent diabetes mellitus (Type 1), By Country, 2020 & 2028 
FIG NO. 18. Global Human insulin Market for Non-Insulin dependent diabetes mellitus (Type 2), Revenue (USD Billion) 2016 – 2028
FIG NO. 19. Comparative Revenue Analysis of Human insulin Market for Non-Insulin dependent diabetes mellitus (Type 2), By Country, 2020 & 2028
FIG NO. 20. Global Human insulin Market Revenue Share, By Region, 2020 & 2028
FIG NO. 21. North America Human insulin Market Revenue, 2016 - 2028 (USD Billion)
FIG NO. 22. Porter’s Five Forces Analysis for Global Human insulin Market
FIG NO. 23. PEST Analysis for Global Human insulin Market
FIG NO. 24. Pricing Analysis for Global Human insulin Market
FIG NO. 25. Value Chain Analysis for Global Human insulin Market
FIG NO. 26. Company Share Analysis, 2019
FIG NO. 27. Radar Determinant Chart, 2019
FIG NO. 28. Company Strategic Developments – Heat Map Analysis
FIG NO. 29. GlaxoSmithCline Business Segment Revenue Share, 2020 (%)
FIG NO. 30. GlaxoSmithCline Geographical Segment Revenue Share, 2020 (%)
FIG NO. 31. Market Channels
FIG NO. 32. Marketing Channel Development Trend
FIG NO. 33. Growth in World Gross Product, 2008-2018
FIG NO. 34. Research Methodology – Detailed View
FIG NO. 35. Research Methodology

Table Of Tables

List of Tables 

TABLE NO. 1. Global Human insulin Market: Snapshot
TABLE NO. 2. Quarterly Human insulin Market Revenue by Region, 2020
TABLE NO. 3. Quarterly Human insulin Market Revenue Forecast by Region, 2021
TABLE NO. 4. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Billion) 
TABLE NO. 5. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Billion) 
TABLE NO. 6. Global Human insulin Market for Drugs, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 7. Global Human insulin Market for Drug Delivery Devices, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 8. Global Human insulin Market for Insulin dependent diabetes mellitus (Type 1), by Region, 2016 – 2028 (USD Billion)
TABLE NO. 9 Global Human insulin Market for Non-Insulin dependent diabetes mellitus (Type 2), by Region, 2016 – 2028 (USD Billion)
TABLE NO. 10. Global Human insulin Market Revenue, By Region, 2016 – 2028 (USD Billion)
TABLE NO. 11. North America Human insulin Market Revenue, By Country, 2016 – 2028 (USD Billion)
TABLE NO. 12. North America Human insulin Market Revenue, By Product, 2016 – 2028 (USD Billion)
TABLE NO. 13. North America Human insulin Market Revenue, By Application, 2016 – 2028 (USD Billion)
TABLE NO. 14. U.S. Human insulin Market Revenue, By Product, 2016 – 2028 (USD Billion)
TABLE NO. 15. U.S. Human insulin Market Revenue, By Application, 2016 – 2028 (USD Billion)
TABLE NO. 16. Canada Human insulin Market Revenue, By Product, 2016 – 2028 (USD Billion)
TABLE NO. 17. Canada Human insulin Market Revenue, By Application, 2016 – 2028 (USD Billion)
TABLE NO. 18. Mexico Human insulin Market Revenue, By Product, 2016 – 2028 (USD Billion)
TABLE NO. 19. Mexico Human insulin Market Revenue, By Application, 2016 – 2028 (USD Billion)
TABLE NO. 20. Drivers for the Human insulin Market: Impact Analysis
TABLE NO. 21. Restraints for the Human insulin Market: Impact Analysis
TABLE NO. 22. Major Buyers of Human insulin  
TABLE NO. 23. Distributors/Traders List of Human insulin
TABLE NO. 24. Global Human insulin Market, Company Market Revenue, 2016 – 2019 (USD Billion)
TABLE NO. 25: Global Human insulin Market, Company Y-o-Y Growth, 2017 – 2019 (USD Billion)